180 Life Sciences [ATNF] vs Regeneron [REGN] Detailed Stock Comparison

180 Life Sciences Corp.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: 180 Life Sciences Corp. wins in 2 metrics, Regeneron Pharmaceuticals, Inc. wins in 13 metrics, with 1 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric 180 Life Sciences Corp. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 0.11 18.00 180 Life Sciences Corp.
Price-to-Book Ratio 7.90 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 26.25 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio 0.00 -4.80 Tie
EV/EBITDA -6.81 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 0.00% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -371.02% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -55.46% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-1.48M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 234.00% 15.66% 180 Life Sciences Corp.
Price-to-Sales Ratio (TTM) N/A 5.50 N/A
Enterprise Value $43.94M $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio N/A 4.95 N/A
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-14.95 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.41 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 47.16% 2.55% Regeneron Pharmaceuticals, Inc.

180 Life Sciences Corp. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

ATNF
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
180 Life Sciences Corp.0.60%748.48%633.62%818.03%1,766.67%2,000.00%
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
180 Life Sciences Corp.234.00%-91.14%-99.60%-99.54%-99.54%-99.54%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: 180 Life Sciences Corp. vs Regeneron Pharmaceuticals, Inc.

MetricATNFREGN
Market Information
Market Cap i$2.57B$80.98B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i11,607,004642,495
90 Day Avg. Volume i10,978,743617,765
Last Close$16.80$614.98
52 Week Range$0.66 - $23.05$503.25 - $821.11
% from 52W High-27.11%-25.10%
All-Time High$4,957.10 (Apr 12, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-99.66%-49.23%
Growth Metrics
Quarterly Revenue GrowthN/A0.03%
Quarterly Earnings GrowthN/A-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i0.00%0.23%
Return on Equity (TTM) i-3.71%0.15%
Debt to Equity (MRQ) i26.259.51
Cash & Liquidity
Book Value per Share (MRQ)$0.89$304.65
Cash per Share (MRQ)$0.37$83.86
Operating Cash Flow (TTM) i$-3,159,107$4.98B
Levered Free Cash Flow (TTM) i$-3,003,669$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: 180 Life Sciences Corp. vs Regeneron Pharmaceuticals, Inc.

MetricATNF (Oct 21, 2025)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i0.1118.00
Forward P/E i-15.3014.21
PEG Ratio i0.00-4.80
Price to Sales (TTM) iN/A5.50
Price to Book (MRQ) i7.902.45
Market Capitalization
Market Capitalization i$2.57B$80.98B
Enterprise Value i$43.94M$70.98B
Enterprise Value Metrics
Enterprise to Revenue iN/A4.95
Enterprise to EBITDA i-6.8116.72
Risk & Other Metrics
Beta i0.410.40
Book Value per Share (MRQ) i$0.89$304.65

Financial Statements Comparison: 180 Life Sciences Corp. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricATNF (2024)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i-14.6%
Gross Profit iN/A12.24B
Gross Margin i-85.4%
Research & Development i1.97M5.85B
Operating Income (EBIT) i-6.32M3.70B
Operating Margin i-25.8%
EBITDA i-4.83M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-6.46M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax i-296,024725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-6.17M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricATNF (2024)REGN (2025)
Cash & Equivalents i4.59M3.12B
Total Current Assets i5.14M18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i3.50M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt i6,6162.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i9.25M31.26B
Retained Earnings i-141.52M35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment iN/A1.54B

Cash Flow Statement Comparison

MetricATNF (2024)REGN (2025)
Operating Cash Flow i-4.57M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures iN/A0
Free Cash Flow i-1.48M3.77B
FCF Margin i-26.3%
Debt Repayment i-1.33MN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricATNFREGN
Shares Short i1.14M2.55M
Short Ratio i0.194.46
Short % of Float i47.16%2.55%
Shares Outstanding i6.04M105.72M
Float Shares i5.04M98.55M
% Held by Insiders i9.99%1.98%
% Held by Institutions i0.06%91.08%
% Held by Public i89.95%6.94%

Dividend Analysis & Yield Comparison: 180 Life Sciences Corp. vs Regeneron Pharmaceuticals, Inc.

MetricATNFREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026